Theradiag: 2020 Half-year Financial Report Publication
23 Settembre 2020 - 5:45PM
Business Wire
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker:
ALTER), a company specializing in in vitro diagnostics and
theranostics, today announces that its half-year financial report
as at 30 June 2020 has been made available to the public and filed
with the French regulator Autorité des Marchés Financiers
(AMF).
It is available in French only directly on THERADIAG's website,
www.theradiag.com in the Investors / Financial News / Financial
Reports section and on www.amf-france.org.
***
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2019, the Company posted revenue of €9.6 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200923005664/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com
NewCap Financial Communications &
Investor Relations Sandrine Boussard-Gallien Quentin
Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas
Mérigeau Tel.: +33 (0)1 44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024